Table 1. Clinical summary of children receiving ciclesonide as their primary treatment for EoE.
| Patients | ||||
|---|---|---|---|---|
| 1 | 2 | 3 | 4 | |
| Age (y) | 4 | 4 | 16 | 7 |
| Sex | Male | Male | Female | Male |
| Weight (kg) | 12.7 | 18 | 49 | 24.5 |
| Dose, total/d (μg) | 320 | 640 | 320 | 320 |
| Food allergy | Y | Y | Y | Y |
| Atopic history | Y | Y | Y | Y |
| Months of treatment | September-November | August-November | August-October | June-August |
| Dietary restriction | Y | Y | Y | Y |
| Pre/Post | Pre/Post | Pre/Post | Pre/Post | |
| Treatment: | ||||
| Symptoms | Slow growth/Weight gain | Reflux, dysphagia, pain/None | Dysphagia/None | Vomiting, dysphagia/None |
| Endoscopic findings: | Normal/Normal | Normal/Normal | Trachealization/Furrowing | Furrowing/Furrowing |
| Histology | ||||
| Proximal biopsy: | ||||
| Eosinophil/hpf (×40) | 58/3 | 105/0 | 46/4 | 75/0 |
| Basal zone hyperplasia | Y/Y | Y/N | Y/N | Y/Y |
| Rete peg elongation | N/N | Y/N | Y/N | Y/N |
| Spongiosis/edema | Y/N | Y/N | N/N | N/N |
| Degranulation | Y/N | N/N | Y/N | N/N |
| Microabscess | N/N | N/N | N/N | N/N |
| Distal biopsy: | ||||
| Eosinophil/hpf (×40) | 75/0 | 100/0 | 30/3 | 100/0 |
| Basal zone hyperplasia | Y/Y | Y/N | Y/N | Y/Y |
| Rete peg elongation | Y/N | Y/N | Y/N | Y/N |
| Spongiosis/edema | N/N | Y/N | N/N | N/N |
| Degranulation | N/N | N/N | Y/N | N/N |
| Microabscess | N/N | N/N | N/N | N/N |
hpf, High-power field; N, no; Pre, before ciclesonide; Post, after ciclesonide; Y, yes.